Bluebird taps Lonza to boost manufacturing capacity for its gene therapies Zynteglo, Skysona
Fierce Pharma
SEPTEMBER 28, 2023
As bluebird bio’s pricey gene therapy launches take flight, the company is boosting manufacturing capacity with Swiss CDMO Lonza. Under the updated deal, Lonza has agreed to increase manufacturing capacity for bluebird’s therapies Zynteglo and Skysona, according to a SEC filing published Wednesday.
Let's personalize your content